

Emily C. Zabor

Curriculum Vitae

485 Lexington Ave, 2nd floor
New York, NY 10017
☎ 646-888-8299
✉ zabore@mskcc.org
🌐 emilyzabor.com

Education

- 2013–Present **Doctor of Public Health**, *Columbia University*, New York, NY, Biostatistics.
Expected graduation December 2018
Dissertation topic: Statistical methods for the study of etiologic heterogeneity
Advisors: Dr. Colin Begg and Dr. Shuang Wang
- 2008–2010 **Master of Science**, *The University of Minnesota*, Minneapolis, MN, Biostatistics.
- 1999–2003 **Bachelor of Arts**, *Grinnell College*, Grinnell, IA, Anthropology.

Professional experience

- 2018–Present **Senior Research Biostatistician**, MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY.
Department of Epidemiology & Biostatistics
- 2015–2017 **Research Biostatistician II**, MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY.
Department of Epidemiology & Biostatistics
- 2012–2015 **Research Biostatistician**, MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY.
Department of Epidemiology & Biostatistics
- 2010–2012 **Assistant Research Biostatistician**, MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY.
Department of Epidemiology & Biostatistics
- 2006–2008 **Account Coordinator**, US BANK, Minneapolis, MN.
Corporate Payment Systems
- 2003–2006 **Volunteer**, US PEACE CORPS, Ghana, West Africa.
Natural Resources for Livelihood Sustainability Program

Teaching experience

- Fall 2017 **Teaching Assistant**, COLUMBIA UNIVERSITY, New York, NY.
Data Science I
- 2016–2017 **Adjunct Professor**, HUNTER COLLEGE, New York, NY.
Fundamentals of Biostatistics
- 2008–2010 **Teaching Assistant**, THE UNIVERSITY OF MINNESOTA, Minneapolis, MN.
Introduction to Biostatistics
Advanced Topics in Clinical Trials

Research experience

- 2009 **Summer Intern in Biomedical Research**, NATIONAL INSTITUTES OF HEALTH, Bethesda, MD.
Eunice Kennedy Shriver National Institute for Child Health & Human Development
- 2009–2010 **Research Assistant**, THE UNIVERSITY OF MINNESOTA, Minneapolis, MN.
Coordinating Centers for Biometric Research
- 2008–2009 **Research Assistant**, THE UNIVERSITY OF MINNESOTA, Minneapolis, MN.
Division of Health Policy and Management

Methodologic publications

1. (Under review) **Zabor, E. C.**, Seshan, S.E., Wang, S., Begg, C. B. Validity of a method for identifying disease subtypes that are etiologically heterogeneous.
2. **Zabor, E. C.**, Coit, D., Gershenwald, J. E., McMasters, K. M., Michaelson, J. S., Stromberg, A. J., & Panageas, K. S. (2018). Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors. *Ann Surg Oncol*, 25(8), 2172-2177.
3. **Zabor, E. C.**, & Begg, C. B. (2017). A comparison of statistical methods for the study of etiologic heterogeneity. *Stat Med*, 36(25), 4050-4060.
4. Mauguen, A., **Zabor, E. C.**, Thomas, N. E., Berwick, M., Seshan, V. E., & Begg, C. B. (2017). Defining Cancer Subtypes With Distinctive Etiologic Profiles: An Application to the Epidemiology of Melanoma. *J Am Stat Assoc*, 112(517), 54-63.
5. Begg, C. B., Rice, M. S., **Zabor, E. C.**, & Tworoger, S. S. (2017). Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries. *Br J Cancer*, 116(8), 1088-1091.
6. **Zabor, E. C.**, Heller, G., Schwartz, L. H., Chapman, P. B. (2016). Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib. *Clin Cancer Res*, 22(6), 1341-1347.
7. Begg, C. B., Orlow, I., **Zabor, E. C.**, Arora, A., Sharma, A., Seshan, V. E., Bernstein, J. L. (2015). Identifying Etiologically Distinct Sub-Types of Cancer: A Demonstration Project Involving Breast Cancer. *Cancer Med*, 4(9), 1432-1439.
8. Begg, C. B., Seshan, V. E., **Zabor, E. C.**, Furberg, H., Arora, A., Shen, R., . . . Hsieh, J. J. (2014). Genomic investigation of etiologic heterogeneity: methodologic challenges. *BMC Med Res Methodol*, 14, 138.
9. **Zabor, E. C.**, Gonen, M., Chapman, P. B., Panageas, K. S. (2013). Dynamic prognostication using conditional survival estimates. *Cancer*, 119(20), 3589-3592.
10. Begg, C. B., **Zabor, E. C.**, Bernstein, J. L., Bernstein, L., Press, M. F., Seshan, V. E. (2013). A conceptual and methodological framework for investigating etiologic heterogeneity. *Stat Med*, 32(29), 5039-5052.
11. Begg, C. B., **Zabor, E. C.** (2012). Detecting and exploiting etiologic heterogeneity in epidemiologic studies. *Am J Epidemiol*, 176(6), 512-518.

Collaborative publications

1. Scott, J. M., **Zabor, E. C.**, Schwitzer, E., Koelwyn, G. J., Adams, S. C., Nilsen, T. S., . . . Jones, L. W. (2018). Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis. *J Clin Oncol*, 36(22), 2297-2305.
2. Romanoff, A., **Zabor, E. C.**, Stempel, M., Sacchini, V., Pusic, A., & Morrow, M. (2018). A Comparison of Patient-Reported Outcomes After Nipple-Sparing Mastectomy and Conventional Mastectomy with Reconstruction. *Ann Surg Oncol*, 25(10), 2909-2916.
3. Moo, T. A., Edelweiss, M., Hajiyeva, S., Stempel, M., Raiss, M., **Zabor, E. C.**, . . . Morrow, M. (2018). Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? *Ann Surg Oncol*, 25(6), 1488-1494.
4. Lee, B. H., **Zabor, E. C.**, Tennenbaum, D., Furberg, H., Benfante, N., Coleman, J. A., . . . Russo, P. (2018). Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol*, 36(2), 257-263.
5. Francis, J. H., Levin, A. M., **Zabor, E. C.**, Gobin, Y. P., & Abramson, D. H. (2018). Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival. *PLoS One*, 13(5), e0197081.
6. Cassidy, M. R., **Zabor, E. C.**, Stempel, M., Mehrara, B., & Gemignani, M. L. (2018). Does response to neo-adjuvant chemotherapy impact breast reconstruction? *Breast J*, 24(4), 567-573.
7. **Zabor, E. C.**, Furberg, H., Lee, B., Campbell, S., Lane, B. R., Thompson, R. H., . . . Russo, P. (2017). Long-term renal functional recovery following radical nephrectomy for kidney cancer: Results from a multi-center confirmatory study. *J Urol*, 199(4), 921-926.
8. Weber, J. J., Jochelson, M. S., Eaton, A., **Zabor, E. C.**, Barrio, A. V., Gemignani, M. L., . . . El-Tamer, M. (2017). MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer: MRI and Pathologic Complete Response. *J Am Coll Surg*, 225(6), 740-746.
9. Winer, A. G., **Zabor, E. C.**, Vacchio, M. J., Hakimi, A. A., Russo, P., Coleman, J. A., & Jaimes, E. A. (2017). The Effect of Patient and Surgical Characteristics on Renal Function After Partial Nephrectomy. *Clin Genitourin Cancer*, 16(3), 191-196.
10. Teo, M. Y., Bambury, R. M., **Zabor, E. C.**, Jordan, E., Al-Ahmadie, H., Boyd, M. E., . . . Rosenberg, J. E. (2017). DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. *Clin Cancer Res*, 23(14), 3610-3618.
11. Schwitzer, E., Orlow, I., **Zabor, E. C.**, Begg, C. B., Berwick, M., Thomas, N. E., . . . Jones, L. W. (2017). No association between prediagnosis exercise and survival in patients with high-risk primary melanoma: A population-based study. *Pigment Cell Melanoma Res*, 30(4), 424-427.
12. Salz, T., **Zabor, E. C.**, de Nully Brown, P., Dalton, S. O., Raghunathan, N. J., Matasar, M. J., . . . Johansen, C. (2017). Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. *J Clin Oncol*, 35(34), 3837-3843.
13. Pilewskie, M., **Zabor, E. C.**, Mamtani, A., Barrio, A. V., Stempel, M., & Morrow, M. (2017). The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype. *Ann Surg Oncol*, 24(12), 3527-3533.

14. McCartan, D. P., **Zabor, E. C.**, Morrow, M., Van Zee, K. J., & El-Tamer, M. B. (2017). Oncologic Outcomes After Treatment for MRI Occult Breast Cancer (pT0N+). *Ann Surg Oncol*, 24(11), 3141-3147.
15. Manley, B. J., **Zabor, E. C.**, Casuscelli, J., Tennenbaum, D. M., Redzematovic, A., Becerra, M. F., ...Hakimi, A. A. (2017). Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. *Eur Urol Focus*, 3(4-5), 421-427.
16. Lee, B. H., **Zabor, E. C.**, Tennenbaum, D., Furberg, H., Benfante, N., Coleman, J. A., . . . Russo, P. (2017). Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol*.
17. Gilbert, E., **Zabor, E. C.**, Stempel, M., Mangino, D., Heerdt, A., & Pilewskie, M. (2017). Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance. *Ann Surg Oncol*, 24(10), 3048-3054.
18. Gentile, L. F., Plitas, G., **Zabor, E. C.**, Stempel, M., Morrow, M., & Barrio, A. V. (2017). Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer. *Ann Surg Oncol*, 24(13), 3896-3902.
19. Francis, J. H., Brodie, S. E., Marr, B., **Zabor, E. C.**, Mondesire-Crump, I., & Abramson, D. H. (2017). Efficacy and Toxicity of Intravitreal Chemotherapy for Retinoblastoma: Four-Year Experience. *Ophthalmology*, 124(4), 488-495.
20. Cho, G. Y., Gennaro, L., Sutton, E. J., **Zabor, E. C.**, Zhang, Z., Giri, D., . . . Thakur, S. B. (2017). Intravoxel incoherent motion (IVIM) histogram biomarkers for prediction of neoadjuvant treatment response in breast cancer patients. *Eur J Radiol Open*, 4, 101-107.
21. Casuscelli, J., Weinhold, N., Gundem, G., Wang, L., **Zabor, E. C.**, Drill, E., . . . Hsieh, J. J. (2017). Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. *JCI Insight*, 2(12).
22. Casuscelli, J., Becerra, M. F., Manley, B. J., **Zabor, E. C.**, Reznik, E., Redzematovic, A., . . . Hakimi, A. A. (2017). Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. *Eur Urol Focus*.
23. Campbell, P. T., Rebbeck, T. R., Nishihara, R., Beck, A. H., Begg, C. B., Bogdanov, A. A., . . . Ogino, S. (2017). Proceedings of the third international molecular pathological epidemiology (MPE) meeting. *Cancer Causes Control*, 28(2), 167-176.
24. Boursiquot, B. C., **Zabor, E. C.**, Glezerman, I. G., & Jaimes, E. A. (2017). Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal Function. *Hypertension*.
25. Alane, S. R., Shah, S., **Zabor, E. C.**, Vijai, J., Ostrovnaya, I., Garcia-Grossman, I. R., . . . Bajorin, D. F. (2017). Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder. *Int J Clin Pharmacol Ther*, 55 (2017)(3), 203-209.
26. **Zabor, E. C.**, Furberg, H., Mashni, J., Lee, B., Jaimes, E. A., Russo, P. (2016). Factors Associated with Recovery of Renal Function following Radical Nephrectomy for Kidney Neoplasms. *Clin J Am Soc Nephrol*, 11(1), 101-107.

27. Yu, A. F., Raikhelkar, J., **Zabor, E. C.**, Tonorezos, E. S., Moskowitz, C. S., Adsuar, R., . . . Liu, J. E. (2016). Two-Dimensional Speckle Tracking Echocardiography Detects Subclinical Left Ventricular Systolic Dysfunction among Adult Survivors of Childhood, Adolescent, and Young Adult Cancer. *Biomed Res Int*, 2016, 9363951.
28. Tully, C. M., Apolo, A. B., **Zabor, E. C.**, Regazzi, A. M., Ostrovnya, I., Furberg, H. F., . . . Bajorin, D. F. (2016). The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. *Cancer*, 122(5), 712-721.
29. Thong, A. E., Petruzella, S., Orlow, I., **Zabor, E. C.**, Ehdaie, B., Ostroff, J. S., . . . Barnes, H. F. (2016). Accuracy of Self-reported Smoking Exposure Among Bladder Cancer Patients Undergoing Surveillance at a Tertiary Referral Center. *Eur Urol Focus*, 2(4), 441-444.
30. Spitzer, B., Perales, M. A., Kernan, N. A., Prockop, S. E., **Zabor, E. C.**, Webb, N., . . . Boulad, F. (2016). Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoablation with Clofarabine, Melphalan, and Thiopeta. *Biol Blood Marrow Transplant*, 22(8), 1449-1454.
31. Murray, K. S., **Zabor, E. C.**, Spaliviero, M., Russo, P., Bazzi, W. M., Musser, J. E., . . . Furberg, H. (2016). Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution. *World J Urol*, 34(12), 1667-1672.
32. Manley, B. J., **Zabor, E. C.**, Casascelli, J., Tennenbaum, D. M., Redzematovic, A., Becerra, M. F., . . . Hakimi, A. A. (2016). Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. *Eur Urol Focus*.
33. Hay, J. L., **Zabor, E. C.**, Kumar, J., Brennessel, D., Kemeny, M. M., Lubetkin, E. I. (2016). Cancer beliefs and patient activation in a diverse, multilingual primary care sample. *Psychooncology*, 25(9), 1071-1078.
34. Desai, N. B., Scott, S. N., **Zabor, E. C.**, Cha, E. K., Hreiki, J., Sfakianos, J. P., . . . Iyer, G. (2016). Genomic characterization of response to chemoradiation in urothelial bladder cancer. *Cancer*, 122(23), 3715-3723.
35. Dahi, P. B., Morawa, E., Perales, M. A., **Zabor, E. C.**, Devlin, S. M., Maloy, M., . . . Giralt, S. A. (2016). Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS. *Bone Marrow Transplant*, 51(7), 991-993.
36. Bagrodia, A., Lee, B. H., Lee, W., Cha, E. K., Sfakianos, J. P., Iyer, G., . . . Feldman, D. R. (2016). Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. *J Clin Oncol*, 34(33), 4000-4007.
37. Bagrodia, A., Cha, E. K., Sfakianos, J. P., **Zabor, E. C.**, Bochner, B. H., Al-Ahmadie, H. A., . . . Coleman, J. A. (2016). Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. *J Urol*, 195(6), 1684-1689.
38. Albiges, L., Hakimi, A. A., Xie, W., McKay, R. R., Simantov, R., Lin, X., . . . Choueiri, T. K. (2016). Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. *J Clin Oncol*.
39. Al-Ahmadie, H. A., Iyer, G., Lee, B. H., Scott, S. N., Mehra, R., Bagrodia, A., . . . Solit, D. B. (2016). Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. *Nat Genet*, 48(4), 356-358.

40. Sfakianos, J. P., Cha, E. K., Iyer, G., Scott, S. N., **Zabor, E. C.**, Shah, R. H., . . . Coleman, J. A. (2015). Genomic Characterization of Upper Tract Urothelial Carcinoma. *Eur Urol*, 68(6), 970-977.
41. Lubetkin, E. I., **Zabor, E. C.**, Isaac, K., Brennessel, D., Kemeny, M. M., Hay, J. L. (2015). Health literacy, information seeking, and trust in information in Haitians. *Am J Health Behav*, 39(3), 441-450.
42. Kim, P. H., Cha, E. K., Sfakianos, J. P., Iyer, G., **Zabor, E. C.**, Scott, S. N., . . . Bochner, B. H. (2015). Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. *Eur Urol*, 67(2), 198-201.
43. Bambury, R. M., Benjamin, D. J., Chaim, J. L., **Zabor, E. C.**, Sullivan, J., Garcia-Grossman, I. R., . . . Rosenberg, J. E. (2015). The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. *Oncologist*, 20(5), 508-515.
44. Sfakianos, J. P., Hakimi, A. A., Kim, P. H., **Zabor, E. C.**, Mano, R., Bernstein, M., . . . Russo, P. (2014). Outcomes in patients undergoing nephrectomy for renal cancer on chronic anticoagulation therapy. *Eur J Surg Oncol*, 40(12), 1700-1705.
45. Mano, R., Hakimi, A. A., **Zabor, E. C.**, Bury, M. A., Donati, O. F., Karlo, C. A., . . . Russo, P. (2014). Association between visceral and subcutaneous adiposity and clinicopathological outcomes in non-metastatic clear cell renal cell carcinoma. *Can Urol Assoc J*, 8(9-10), E675-680.
46. Lubetkin, E. I., **Zabor, E. C.**, Brennessel, D., Kemeny, M. M., Hay, J. L. (2014). Beyond demographics: differences in patient activation across new immigrant, diverse language subgroups. *J Community Health*, 39(1), 40-49.
47. Hayes, S. A., Soff, G. A., **Zabor, E. C.**, Moskowitz, C. S., Liu, C. C., Ginsberg, M. S. (2014). Clinical consequences of an indeterminate CT pulmonary angiogram in cancer patients. *Clin Imaging*, 38(5), 637-640.
48. Ehdaie, B., Furberg, H., **Zabor, E. C.**, Hakimi, A. A., Russo, P. (2014). Comprehensive assessment of the impact of cigarette smoking on survival of clear cell kidney cancer. *J Urol*, 191(3), 597-602.
49. Do, R. K., Katz, S. S., Gollub, M. J., Li, J., LaFemina, J., **Zabor, E. C.**, . . . Allen, P. J. (2014). Interobserver agreement for detection of malignant features of intraductal papillary mucinous neoplasms of the pancreas on MDCT. *AJR Am J Roentgenol*, 203(5), 973-979.
50. **Zabor, E. C.**, Li, Y., Thornton, L. M., Shuman, M. R., Bulik, C. M., Lichtenstein, P., . . . Furberg, H. (2013). Initial reactions to tobacco use and risk of future regular use. *Nicotine Tob Res*, 15(2), 509-517.
51. Weiss, M. J., Ito, H., Araujo, R. L., **Zabor, E. C.**, Gonen, M., D'Angelica, M. I., . . . Jarnagin, W. R. (2013). Hepatic pedicle clamping during hepatic resection for colorectal liver metastases: no impact on survival or hepatic recurrence. *Ann Surg Oncol*, 20(1), 285-294.
52. Rink, M., **Zabor, E. C.**, Furberg, H., Xylinas, E., Ehdaie, B., Novara, G., . . . Shariat, S. F. (2013). Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. *Eur Urol*, 64(3), 456-464.
53. Rink, M., Furberg, H., **Zabor, E. C.**, Xylinas, E., Babjuk, M., Pycha, A., . . . Shariat, S. F. (2013). Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. *Eur Urol*, 63(4), 724-732.

54. Ridge, C. A., Huang, J., Cardoza, S., **Zabor, E. C.**, Moskowitz, C. S., Zakowski, M. F., Ginsberg, M. S. (2013). Comparison of multiplanar reformatted CT lung tumor measurements to axial tumor measurement alone: impact on maximal tumor dimension and T stage. *AJR Am J Roentgenol*, 201(5), 959-963.
55. Pannu, H. K., Ma, W., **Zabor, E. C.**, Moskowitz, C. S., Barakat, R. R., Hricak, H. (2013). Enhancement of ovarian malignancy on clinical contrast enhanced MRI studies. *ISRN Obstet Gynecol*, 2013, 979345.
56. Moskowitz, C. S., **Zabor, E. C.**, Jochelson, M. (2013). Response to the "letter to the editor" by Dr. Thomas Filleron. *Breast J*, 19(2), 227.
57. McErlean, A., Panicek, D. M., **Zabor, E. C.**, Moskowitz, C. S., Bitar, R., Motzer, R. J., . . . Ginsberg, M. S. (2013). Intra- and interobserver variability in CT measurements in oncology. *Radiology*, 269(2), 451-459.
58. McErlean, A., Huang, J., **Zabor, E. C.**, Moskowitz, C. S., Ginsberg, M. S. (2013). Distinguishing benign thymic lesions from early-stage thymic malignancies on computed tomography. *J Thorac Oncol*, 8(7), 967-973.
59. Lefkowitz, R. A., Landa, J., Hwang, S., **Zabor, E. C.**, Moskowitz, C. S., Agaram, N. P., Panicek, D. M. (2013). Myxofibrosarcoma: prevalence and diagnostic value of the "tail sign" on magnetic resonance imaging. *Skeletal Radiol*, 42(6), 809-818.
60. Iyer, G., Al-Ahmadie, H., Schultz, N., Hanrahan, A. J., Ostrovnaya, I., Balar, A. V., . . . Solit, D. B. (2013). Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. *J Clin Oncol*, 31(25), 3133-3140.
61. Hakimi, A. A., Furberg, H., **Zabor, E. C.**, Jacobsen, A., Schultz, N., Ciriello, G., . . . Russo, P. (2013). An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. *J Natl Cancer Inst*, 105(24), 1862-1870.
62. Ehdaie, B., Furberg, H., **Zabor, E. C.**, Ostroff, J. S., Shariat, S. F., Bochner, B. H., . . . Dalbagni, G. (2013). Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. *BJU Int*, 111(4), 589-595.
63. Moskowitz, C. S., **Zabor, E. C.**, Jochelson, M. (2012). Breast imaging: understanding how accuracy is measured when lesions are the unit of analysis. *Breast J*, 18(6), 557-563.
64. Kadota, K., Suzuki, K., Kachala, S. S., **Zabor, E. C.**, Sima, C. S., Moreira, A. L., . . . Travis, W. D. (2012). A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. *Mod Pathol*, 25(8), 1117-1127.
65. Kadota, K., Colovos, C., Suzuki, K., Rizk, N. P., Dunphy, M. P., **Zabor, E. C.**, . . . Adusumilli, P. S. (2012). FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. *Ann Surg Oncol*, 19(11), 3598-3605.
66. Abramson, D. H., Marr, B. P., Dunkel, I. J., Brodie, S., **Zabor, E. C.**, Driscoll, S. J., Gobin, Y. P. (2012). Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. *Br J Ophthalmol*, 96(4), 499-502.
67. Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., . . . Joyce, J. A. (2011). Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. *Genes Dev*, 25(23), 2465-2479.
68. Brader, P., Abramson, S. J., Price, A. P., Ishill, N. M., **Zabor, E. C.**, Moskowitz, C. S., . . . Ginsberg, M. S. (2011). Do characteristics of pulmonary nodules on computed tomography in children with known osteosarcoma help distinguish whether the nodules are malignant or benign? *J Pediatr Surg*, 46(4), 729-735.

69. **Zabor, E. C.**, Klebanoff, M., Yu, K., Zhang, J., Nansel, T., Andrews, W., . . . Jeffcoat, M. (2010). Association between periodontal disease, bacterial vaginosis, and sexual risk behaviours. *J Clin Periodontol*, 37(10), 888-893.

R Packages

- riskclustr: functions related to the study of etiologic heterogeneity, <https://github.com/zabore/riskclustr>. *Note that this package is currently under development.*
- condsurv: calculation and plotting of conditional survival estimates, <https://github.com/zabore/condsurv>. *Note that this package is currently under development.*
- ezfun: convenience and utility functions for use in my clinical applications work, with a focus on producing tables for R Markdown output to Microsoft Word, <https://github.com/zabore/ezfun>. *Note that this package is primarily for personal use.*

R Tutorials

- “Survival Analysis in R.” Memorial Sloan Kettering Cancer Center Department of Strategy & Innovation R Presenter Series. August 30, 2018. Materials available online at http://www.emilyzabor.com/tutorials/survival_analysis_in_r_tutorial.html
- “Creating Websites in R.” Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics R User Group. January 23, 2018. Re-presented at the R-Ladies NYC Meetup on February 15, 2018. Materials available online at http://www.emilyzabor.com/tutorials/rmarkdown_websites_tutorial.html
- “Demonstration of utility functions for R Markdown reports in Word.” Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics R User Group. December 6, 2016.
- “Longitudinal data analysis.” Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics Masters Seminar Series. July 28, 2015.
- “Conditional survival.” Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics Masters Seminar Series. November 13, 2012.
- “Binary recursive partitioning with rpart and rpart.plot.” Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics Masters Seminar Series. August 23, 2011.

Presentations

Invited

- “Teaching survival analysis to clinical collaborators.” R/Medicine Conference, New Haven, CT, September 7, 2018.
- “How long will I live? The statistics behind prognosis in cancer research.” New York R Conference, New York, NY, April 21, 2018.

Contributed

- “Validity of a method for identifying disease subtypes that are etiologically heterogeneous.” Joint oral and poster presentation at the Joint Statistical Meetings, Vancouver, BC, Canada, July 31, 2018.
- “Validity of a method for identifying disease subtypes that are etiologically heterogeneous.” Eastern North American Region of the International Biometric Society, Atlanta, GA, March 27, 2018.

- “Dimension reduction in the study of etiologic heterogeneity, Oral presentation.” Joint Statistical Meetings, Baltimore, MD, August 1, 2017.
- “A comparison of statistical methods for the study of etiologic heterogeneity.” Poster presentation at the Society for Epidemiologic Research, Seattle, WA, June 20, 2017.
- “A comparison of statistical methods for the study of etiologic heterogeneity.” Poster presentation at the Eastern North American Region of the International Biometric Society, Washington DC, March 12, 2017.
- “A review of statistical methods for evaluating etiologic heterogeneity.” Third International Molecular Pathologic Epidemiology Meeting, Boston, MA, May 12, 2016.
- “Initial reactions to tobacco and risk of future regular tobacco use.” Poster presentation at the Third North American Congress of Epidemiology, Montreal, QC, Canada, June 23, 2011.
- “Association between periodontal disease, bacterial vaginosis, and sexual risk behaviours.” Oral presentation at the American Association for Dental Research Meetings, Washington DC, March 5, 2010.

Service and memberships

Intramural

- 2018-Present Founder and Chair, Memorial Sloan Kettering Department of Epidemiology & Biostatistics Coding Workshop. Introduced a monthly workshop with the goal of learning best practices for coding style and efficiency, through peer-review of code.
- 2016-Present Member, Memorial Sloan Kettering Department of Epidemiology & Biostatistics R User Group

Extramural

- 2016-Present Board member, R-Ladies NYC. R-Ladies is a worldwide organization to promote gender equality in the R programming community. As a board member I assist in planning monthly meetings where women and gender minorities in our local R community present on topics related to their work in R. From January 2017-December 2018, I was the lead organizer of the quarterly R-Ladies NYC book club. In November 2018 I used R blogdown to write the R-Ladies NYC website (<http://www.rladiesnyc.org/>) and have served as the webmaster from November 2018-Present.
- 2018-Present Editorial Board of Statisticians, Journal of Urology. After four years serving as an *ad hoc* statistical reviewer, in January 2018 I joined a 10-member editorial board comprised of statisticians. In addition to performing statistical peer review, we have collaborated to establish statistical guidelines for the journal to give authors a reference when preparing manuscripts and to expedite the review process.
- 2018-Present *Ad hoc* reviewer, Journal of the American Statistical Association
- 2017-Present *Ad hoc* reviewer, Journal of Clinical Oncology
- 2013-2017 *Ad hoc* statistical reviewer, Journal of Urology

Memberships

- 2017-Present Society for Epidemiologic Research, Member
- 2015-Present American Society of Clinical Oncology, Member
- 2011-Present Eastern North American Region of the International Biometric Society, Member
- 2010-Present American Statistical Association, Member

■ Honors and awards

- 2017 Travel Awardee, American Statistical Association Section on Statistics in Epidemiology
- 2009 Outstanding Teaching Assistant Award, The University of Minnesota
- 2003 Ralph A. Leubben Prize for Anthropology, Grinnell College
- 2002-2003 Mortar Board Honor Society, Grinnell College